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INTRODUCTION 
Chronic obstructive pulmonary disease (COPD) is a major cause of 
morbidity and mortality. It kills more than 3 million people every year, 
making it the 4th largest cause of death in the world. It has been 
estimated that by the year 2030, COPD will become the third biggest 
cause of death
1
. Half a million people die every year due to COPD in 
India.
2 
  COPD results from a chronic inflammatory response which 
induces parenchymal tissue destruction resulting in emphysema and small 
airway fibrosis. These pathological changes result in air trapping and 
progressive airflow limitation. 
 The goals of COPD assessment are to determine the severity of 
disease, including severity of airflow limitation, the impact of patient’s 
health status and risk of future events. 
 Usually the severity of COPD is assessed by validated 
questionnaires such as COPD assessment test (CAT) and Modified 
British Medical Research Council (mMRC) Questionnaire. Airflow 
limitation severity in COPD patients is assessed by spirometric 
evaluation. Spirometry is the most reproducible and objective 
measurement of airflow limitation.  
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 COPD is associated with both airway and systemic inflammation. 
Studies have shown airway and systemic inflammatory markers, such as 
acute phase reactants (CRP and fibrinogen) increase over time and are 
associated with faster decline in lung function and increase during acute 
exacerbations. 
 Interleukin 6(IL-6) has many biological functions, including 
growth and differentiation of B cells, T cells and haematopoietic cells. 
Monocytes appear to be major cell producing IL-6. IL-6 has a rather 
interesting function that makes it an attractive biomarker in COPD. IL-6 
is the primary cytokine regulator of both CRP and fibrinogen in the liver. 
It also plays a critical role in haematopoiesis, causing thrombocytosis and 
leucocytosis with its overexpression. 
 Interestingly, even during clinical stability, COPD patients have 
elevated blood levels of CRP, fibrinogen, leukocytes, and platelets 
compared with healthy control subjects. Since all of these molecules are 
regulated by IL-6, IL-6 may play a salient role in the systemic 
inflammatory responses in COPD. Furthermore, overexpression of IL-6 
in serum or plasma has been associated with dyspnea, skeletal muscle 
weakness, insulin resistance, pulmonary arterial hypertension, and 
exacerbations in COPD patients. 
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 Walter et al
75
 demonstrated the relationship between FEV1 and 
serum IL-6. This study aims to assess serum IL-6 as a marker of severity 
of COPD and its association with acute exacerbations. Thus IL 6 
interpretations can be related to the clinical and prognostic parameters 
and can be useful for evaluation of the therapy instituted for the disease. 
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AIMS AND OBJECTIVES 
Primary Objective  
To assess the severity of COPD by clinical methods and spirometry. 
Secondary Objective 
To find out the correlation between severity of COPD and serum 
Interleukin-6 levels. 
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REVIEW OF LITERATURE 
Definition of COPD: 
 A common preventable and treatable disease is characterised by 
persistent airflow limitation that is usually progressive and associated 
with enhanced chronic inflammatory response in the airway and lung to 
noxious particles. 
Epidemiology: 
 COPD is a major public health problem. Globally, COPD has 
emerged as the major cause of morbidity and mortality expected to 
become the 3rd most leading cause of death and the 5th leading cause of 
loss of ‘Disability Adjusted Life Years’ (DALYs) as per projection of the 
Global Burden of Disease Study (GBDS).
4 
 In India overall prevalence rates of COPD is 5.0 and 3.2 percent 
respectively in men and women of, and over 35 years of age.
5 
The total burden of COPD has more than doubled to about 14.84 million 
in 2011 from about 6.45 million in 1971. 
6 
 
 
 
 The prevalence of COPD is much larger than the estimates given. 
This is attributable to  
1. Patient factors: Patients in the early stages of the disease do not 
seek medical attention due to minimal or complete lack of 
symptoms. 
2. The variable and inaccurate definitions make it hard to quantify 
the burden of the disease. 
 According to a report published by the National Centre for 
Macroeconomics and Health, the estimated economic loss due to COPD 
in India is around Rs 35,000 crores.
3
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RISK FACTORS: 
Smoking: 
 Tobacco smoking is the most common risk factor for COPD. On 
average cigarette smokers have high annual fall in FEV1 of about 50ml, 
whereas in non-smokers rate of fall in FEV1 is around 30ml.Stopping 
smoking does not help in improving FEV1, but subsequent fall is 
reduced. Risk for COPD in smoking depends on the intensity of smoking 
and also type of smoking. Although prevalence of COPD in pipe and 
cigar smoking is higher than that of non-smoker, but when compared with 
cigarette smoking it is lower 
6
. Higher prevalence rate of COPD in males 
are also explained by higher rate of smoking in males. 
Passive Smoking: 
 Not only active smoking, but passive smoking also increases the risk 
of development of COPD. Significant exposure to passive smoking of 
tobacco in childhood associated with lower level of FEV1 in later age 
group. Significant exposure of tobacco smoking in utero also increases 
the reduced the lung function in post natal period.
6 
Air pollution: 
 When compare to rural area prevalence of COPD is higher in 
urbanised area due to exposure of highly polluted air. Prolonged exposure 
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to smoke produced by biomass combustion (a common mode of cooking 
in some areas.) also increases the risk for COPD among women in those 
areas.
7
 
Occupation: 
 Following occupations are associated with increased for COPD: 
1. Coal miners8 
2. Exposure welding fumes in shipyard workers9 
3. Workers exposed to cadmium.10 
Airway hyper responsiveness: 
 Increased airway responsiveness is also a significant predictor for 
subsequent decline in lung function. 
Genetic considerations: 
α 1 antitrypsin deficiency: 
 About one to two% of COPD patients are severe α1 AT deficiency as 
a contributing cause for COPD
11
. Onset of symptoms and death occur 
earlier in alfa1 AT deficiency with smokers than in non-smokers with α1 
AT deficiency. Since specific treatment for a α1 AT deficiency is 
available it should be diagnosed in suspected cases. 
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Other genetic risk factors: 
 A region near the HHIP gene on chromosome 4 and cluster of genes 
on chromosomes 15 contain COPD determinants. 
Nutritional status: 
 IUGR babies and childhood malnutrition are risk factors for COPD 
due to defective lung maturation
12
. 
 
NATURAL HISTORY 
 Factors that contribute to the natural history of COPD include early 
life events such as intrauterine lung development and childhood and 
adolescent lung growth as well as later events such as adult lung 
exposures. The natural history of COPD, therefore, extends over the 
entire life span of the individual; in fact, potential effects could precede 
conception.  
 Because COPD develops slowly, the early stages of the illness are 
often “silent.” Exertional dyspnea in COPD patients is believed to result, 
in large part, from dynamic hyperinflation, which develops with 
increasing respiratory rate.
13
 The COPD patient, therefore, can avoid 
dyspnea by avoiding tachypnea, which can be achieved by decreasing 
10 
 
exercise. As a result, COPD patients become progressively more 
sedentary. The lack of activity in COPD patients result in severe muscle 
wasting. Skeletal muscle is also abnormal because of the effects of 
systemic inflammation. Muscle weakness is a major feature of COPD and 
often limits exercise more than dyspnea does. This may help explain the 
observation that health status is more closely related to exercise 
performance than to lung function.
14 
 In the human, the conducting airways are developed by the 16th week 
of gestation.
15
 Gas exchange structures, including respiratory bronchioles 
and alveoli, develop subsequently. Some alveoli are present at birth, but 
branching of alveolar wall continues postnatally for several years. 
Alveolar number does not increase after age 8, and subsequent growth of 
the lung is due to increase in alveolar size. The airway increases in 
diameter, but not in number, throughout this later growth process. As a 
result, maximal lung function is attained in young adulthood. This level 
of function remains relatively constant for perhaps 10 and then begins to 
decline in a slowly accelerating manner.
16 
11 
 
 
Fig 2: NATURAL HISTORY OF COPD 
 Over 50 years of adult life, a normal individual may lose 1 L of 
FEV1, a decline that averages 20 mL/year, but this decline is not linear 
and probably accelerates with increasing age patient over time. 
Nevertheless, despite the large gaps in understanding the natural history 
of COPD particularly for effects outside the lung and for exposures other 
than cigarette smoking, a number of important features have been 
described. 
 Smoking affects this natural history in several ways. First, smoking 
during the years of lung growth reduces maximally attained lung 
function.
17
 Second, the “plateau phase” is reduced in duration and may be 
absent.
18
 Finally, the rate at which lung function declines is probably 
12 
 
increased. As a result of these various effects, the average smoker loses 
about 2 L of FEV1 over 50 years, an average decline of about 40 mL/yr. 
Smoking cessation in adulthood can slow the rate of decline among 
individuals with mild COPD.
19
 Whether such benefits can be expected 
among individuals with more severe disease or in the elderly is unclear,
20 
although smoking cessation has many other established benefits. 
 Decline in lung function, moreover, may not be continuous. 
Exacerbations, which are characterized by acutely compromised lung 
function, may not completely resolve and may result in stepwise 
decrements of lung function.
21  
Finally, some individuals may experience 
a rapid decline in lung function. Starvation, for example, has been 
reported to cause the accelerated development of emphysema in both 
animal models and humans. Individuals who are “rapid decliners” have 
been observed in prospective studies. Compared to those with a more 
normal FEV1, those with a low FEV1 probably had, and will continue to 
have, a more rapid rate of decline of FEV1 and will be more likely to 
develop COPD, a prediction known as the “horse-racing effect”.
22 
Interestingly, prospective studies have found that decrease in lung 
function is more rapid in individuals with less severe COPD. 
Identification of slow and rapid decliners in longitudinal studies such as 
the Lung Health Study has allowed investigation of biomarkers to 
13 
 
distinguish these groups and to define the mechanistic bases for lung 
function decline.
23 
 Importantly, systemic markers of inflammation have been associated 
with poorer lung function 
24
 and increased rate of decline in lung 
function. 
Early Disease 
 Treatment goals in COPD are largely focused on alleviation of 
symptoms. Because patients with early disease often have no complaints, 
the importance of identifying individuals with early disease was not 
recognized until recently. Individuals with mild lung function have 
increased mortality when compare to normal people, which is primarily 
due to acute cardiac events.
25
 This relationship is true for both smokers 
and nonsmokers. The link between cardiac events and mild COPD may 
be systemic inflammation. Identifying a group of individuals with 
increased cardiac risk, and identifying that they may need treatment to 
benefit maximally from an exercise training program has potential 
clinical benefit. 
Advancing Disease: 
 As FEV1 declines, risk for mortality increases. Cardiac events remain 
a major cause of death, even when COPD is severe. The relative 
14 
 
incidence of death due to respiratory causes, however, increases with 
increasing severity of lung function compromise. 
  Exacerbations, which increase in frequency as FEV1declines, are 
times at which individuals are at particular risk for death. Mortality is 
also increased among those who have recovered from an exacerbation. 
The 2-year mortality rate for patients admitted for acute exacerbation of 
COPD with CO2 retention in the SUPPORT (Study to Understand 
Prognoses and Preferences for Outcomes and Risks of Treatments) trial 
was 49%.
26
 In a retrospective study of a large Canadian database, 1-year 
mortality of 30% to 40% was observed following hospitalization for 
COPD exacerbation among individuals over the age of 65, although 
survival may have been influenced by treatment.
27
 However, studies from 
several centers have shown that some patients with severe obstructive 
airway disease may survive for many years.
28-30
 Thus, it is not possible to 
predict the course of an individual with a high degree of certainty.  
 Decisions relating to level of care and end-of-life issues, therefore, 
must be individualized and must be based on many factors in addition to 
lung function. 
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PATHOLOGY: 
Airway Disease—Chronic Bronchitis: 
 The changes in the airway may occur in both large and small airways:  
 Small airways refer to bronchioles that are less than 2 mm in 
diameter. Cigarette smoking has propensity to affect both airways as well 
as air spaces. Air way remodelling is characteristic of COPD which is 
responsible for airway obstruction. The changes observed in the airway 
include: 
1.   Goblet cell hyperplasia: Not only is there an increase in the 
number of cells, there is also evidence of glandular hyperplasia. 
These changes lead to an increase in mucus production. An 
important trigger for mucin production is neutrophil elastase, which 
act through TGFα and EGFR to upregulate the mucin gene and 
enhance mucin production. Oxidants and metalloproteinases also act 
through the EGFR pathway to increase mucus secretion. 
2.  Epithelial injury and fibrosis: Various environmental insults like 
cigarette smoke and oxidants result in an epithelial injury. Aberrant 
regeneration results in an unchecked fibroblast proliferation. Excess 
fibroblast activity results in peribronchial fibrosis which results in 
airway narrowing and limitation. Matrix metalloproteinase 9(MMP 
9) activates transforming growth factor beta and promotes fibrosis. 
3.  Smooth muscle hypertrophy 
16 
 
4.  Inflammatory Cells: 
Role of neutrophils:  
 Cigarette smoke leads to recruitment of several inflammatory and 
immune cell types in the airspace.
31
 Neutrophils rapidly accumulate in the 
lung in response to cigarette smoke. Recruitment occurs via stimulation 
of epithelial cells and macrophages by cigarette smoke, resulting in 
release of TNF-α and neutrophil chemokines.  
 Oxidants present in smoke and those generated by the inflammatory 
cells also promote neutrophilic inflammation. Oxidants also play a role in 
cigarette smoke–induced cell death. Upon neutrophil activation, 
secondary and tertiary granules containing MMPs, particularly MMP-9, 
are readily released.  
  In addition to causing matrix destruction, proteinases from the 
neutrophil and other cells generate fragments of ECM proteins such as 
collagen.
32
 and laminin
33
 that are also chemotactic for neutrophils, 
leading to a vicious feedback circle of inflammation and tissue 
destruction. 
Role of macrophages: 
 COPD is characterized by a gradual, progressive accumulation of 
macrophages in the lung. Activation of constitutive macrophages leads to 
production of both neutrophil chemokine and cytokines as well as 
production of macrophage chemotactic protein-1, which recruits more 
17 
 
monocytes from the peripheral blood, which later differentiate into 
macrophages. In addition, proteolyzed elastin fragments are chemotactic 
for macrophages. 
 Macrophages have the capacity to produce a variety of MMPs, 
particularly elastases such as MMP-9 and MMP-12, and thus participate 
directly in lung destruction.  
Role of T lymphocytes: 
 Both CD8+ and CD4+ T cells are also increased in airway walls and 
alveoli of patients with COPD, with CD8+ cells predominant.
34 
Airway 
epithelial cells in smokers with COPD have increased expression of 
CXCL10, the ligand for CXCR3 that is expressed on T cells and 
macrophages. 
 Cytotoxic T cells may target epithelial cells and induce cell death, 
particularly those with (latent) viral infection. Other hematopoietic cells 
such as dendritic cells, eosinophils, and mast cells have also been 
observed in COPD, but their roles in the disease process are less well 
defined. 
Role of B cells: 
 Recognition of the increased numbers of B cells and lymphoid 
follicles in the lung has led to the notion of COPD as an autoimmune 
disease. In fact, elastin fragments themselves have been shown to serve as 
autoantigens.  
18 
 
 In summary, multiple inflammatory cell types are present in the lung 
in response to cigarette smoking and interact to cause COPD. 
 
Lung parenchyma – Emphysema: 
 Pulmonary emphysema is defined as destruction and enlargement of 
air spaces distal to the terminal bronchiole. Emphysema is characterized 
by destruction of gas-exchanging air spaces including respiratory 
bronchioles, alveolar ducts, and alveoli. 
  It should be differentiated from other forms of air trapping in which 
there is no destruction. Simple air space enlargement, in which there is no 
destruction or loss of orderly appearance of the lung acinus occurs in the 
contralateral lung following pneumonectomy. Air spaces, particularly 
alveolar ducts, enlarge with advancing age, resulting in what has been 
termed “senile emphysema. 
Alveolar destruction and airway fibrosis in COPD: 
 Alveolar destruction is mediated by proteinases. Proteinases include 
matrix metalloproteinases (MMPs) and neutrophil elastase (NE). 
 
PROTEINASE-ANTIPROTEINASE HYPOTHESIS:  
 There are four classes of proteinases, serine, cysteine, aspartic and 
metalloproteinases, which are distinguished by their mechanism of 
catalysis and endogenous inhibitors. 
19 
 
1. Serine Proteinases: 
The serine proteinase NE was first implicated in COPD after the findings 
that patients deficient in its endogenous inhibitor, A1PI, are at increased 
risk for emphysema and that instillation of NE caused emphysema in 
experimental models. NE also plays a role in airway disease. In fact, NE 
is one of the most potent secretagogues.
35
 In addition, NE is involved in 
monocyte transvascular migration
36
.Despite intense interest in the 
development of NE inhibitors over the years, they remain largely untested 
in terms of their efficacy in COPD. 
 The role of NE in emphysema is due to a direct effect of NE on 
elastin as well as to the ability of NE to inactivate TIMPs and mediate 
monocyte migration into the lung. NE is a potent bactericidal and 
fungicidal agent that acts within the neutrophil lysosome.
37,38 
 Two other serine proteinases that are also neutrophil and monocyte 
derived are cathepsin G (CG) and proteinase 3 (PR3). There is some 
evidence from animal models that PR3, which has some elastolytic 
capacity, may also be involved in the development of COPD.
39 
2. Matrix Metalloproteinases: 
 MMPs represent a family of 24 enzymes that require coordination of 
zinc at the active site, have overlapping substrate specificity, and are 
inhibited by TIMPs.
40
 Several MMPs degrade elastin and hence are likely 
to contribute to emphysema including MMP-2, MMP-9 (gelatinase A and 
20 
 
B), MMP-7 (matrilysin), and MMP-12 (macrophage elastase). MMP-1, -
8, -13 are collagenases, and thus degrade another critical matrix 
component. 
 Several MMPs have been associated with human COPD including 
MMP-1, MMP-9, MT1-MMP, and MMP-12.
41-43
 Macrophages have the 
capacity to produce MMP-1, MMP-3, MMP-7, MMP-9, MMP-12, and 
MMP-19. MMP-12 has been found in macrophages of smokers. MMP-9 
has been detected in macrophages of smokers with COPD and has been a 
prime therapeutic target.
45
 MMP-9 and MMP-8 (neutrophil collagenase) 
are also stored in neutrophil-specific granules.  
3. Cysteine Proteinases: 
 The cysteine proteinase family includes several highly elastolytic 
enzymes.
46 
Although predominantly intracellular enzymes that work most 
effectively in an acidic pH, several cysteine proteinases retain significant 
activity at neutral pH. Moreover, it is possible that cells have the capacity 
to acidify their immediate extracellular environment.
47
 Overall, 
cathepsins are widely expressed in the lung. Cathepsin L,S, and K are 
macrophage products. In addition to ECM catalysis, a normal function of 
cathepsin S is to process antigens in T cells.
48
 Cathepsin K is the most 
potent elastase and collagenase and, hence, might be quite destructive in 
COPD if present. Cathepsin B is an epithelial cell product that has been 
shown to have pro apoptotic properties.
49
. Cathepsins have the potential 
21 
 
to contribute to COPD, although they have been less thoroughly studied 
than other classes of proteinases. 
 
Proteinase Functions in Chronic Obstructive Pulmonary Disease: 
 A variety of proteinases participate in COPD, with their major role 
being destruction of ECM components, particularly elastin. However, 
proteinases also regulate inflammation, not only by blazing trails for cells 
through tissue barriers, but also via both the generation and the 
degradation of chemokines and cytokines MMPs also limit inflammation 
via processing of chemokines. 
 Within the airways, NE induces mucus secretion, as mentioned 
previously. This response is mediated by NE-dependent proteolytic 
activation of EGFR via a TGF-α–dependent mechanism. MMP-9 has 
been shown to activate TGF-ß and mediate airway fibrosis in COPD. 
Thus, proteinases participate in multiple activities at several anatomic 
lung sites in the development of COPD.  
 Fibrosis of airways and lung parenchyma is also a feature of COPD. 
Production of IFN-gamma by T cells and transforming growth factor-ß 
(TGF-ß) by several cell types contributes to accumulation of collagen. 
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ALPHA1-PROTEASE INHIBITOR DEFICIENCY: 
Physiologic Role of Alpha1-Protease Inhibitor: 
 A1PI is a serine proteinase inhibitor that is a prominent protein in the 
serum. A1PI is also commonly known as alpha1-antitrypsin. The protein 
is produced mainly in the liver, is found in high concentrations in the 
blood stream, and permeates tissues including the lung.   
 Serine proteinases whose activities are inhibited by A1PI include 
pancreatic trypsin, chymotrypsin, NE, and proteases from some 
microorganisms. However, its main substrate in vivo is believed to be 
NE.
69
 
Genetic Variations: 
 A1PI is a 52-kDa glycoprotein composed of 394 amino acids, and 
it is coded for by a single gene on chromosome 14. The serum protease 
inhibitor phenotype (Pi type) is determined by the independent expression 
of the two parental alleles. The A1PI gene is highly pleomorphic. More 
than 75 alleles are known, and they have been classified into normal 
(associated with normal serum levels of normally functioning A1PI), 
deficient (associated with serum A1PI levels lower than normal), null 
(associated with undetectable A1PI in the serum), and dysfunctional 
(A1PI is present in normal amount but does not function 
normally).
69 
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 The normal M alleles (the alleles are assigned a letter code) are found 
in about 90% of persons of European descent with normal serum A1PI 
levels; their phenotype is designated Pi MM. Normal values of serum 
A1PI are 150 to 350 mg/dl. More than 95% of persons in the severely 
deficient category are homozygous for the Z allele, designated Pi ZZ, and 
have decreased serum A1PI levels. Pi null, found in homozygous form as 
Pi null-null and found in heterozygous form with a deficient allele as Pi Z 
null. 
Lung disease in alpha1 protease inhibitor deficient phenotypes: 
 The premature development of severe emphysema is the hallmark of 
homozygous A1PI deficiency.
50
 Symptoms or signs of pulmonary disease 
rarely develop before age 25 years. The onset of dyspnea occurs at a 
median age of 40 years in Pi Z smokers and 53 years in nonsmokers.
51-52 
 In the 1970s, it was stated that more than half of those with type Pi Z  
die from pulmonary disease,
50
 and this probably remains the case today. 
 Tobacco smoking and the development of pulmonary disease are 
strongly associated. Smokers who are type Pi Z have a significantly lower 
life expectancy than nonsmokers who are type Pi Z. Annual decline of 
FEV1 is greater than normal in nonsmokers who are type Pi Z, but it is 
much greater in smokers who are type Pi Z than in nonsmokers.
54 
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  In addition to cigarette smoking, asthma, recurrent respiratory 
infections, and unidentified genetic factors have been suggested as 
possible risk factors for chronic airflow limitation. 
 Radiographically, Pi Z patients characteristically have more definite 
evidence of emphysema than seen with garden-variety COPD. The 
finding of basilar emphysema is not constant in Pi Z patients, but when 
present, it is strongly suggestive of the diagnosis. It is common with 
advanced disease to see hairline arcuate shadows separating markedly 
radiolucent areas in the lung bases from the less severely involved upper 
portions of the lungs 
 
TYPES OF EMPHYSEMA: 
 Localization of the lesions of mild emphysema in the acinus serves as 
the basis for classification into several types of emphysema. The acinus 
or secondary lung lobule is the unit of lung structure distal to the terminal 
bronchiole. The acinus is composed of three to five orders of respiratory 
bronchioles, which have alveoli originating directly from their walls. All 
of the structures distal to the terminal bronchiole participate in gas 
exchange and constitute the respiratory tissues of the lungs 
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Classification Of Respiratory Air Space Enlargement: 
Simple Air Space Enlargement 
Congenital 
• Congenital lobar over inflation 
• Down syndrome 
Acquired 
• Secondary to loss of lung volume 
EMPHYSEMA 
Proximal acinar emphysema 
• Focal emphysema 
• Centriacinar emphysema  
Panacinar emphysema 
 The most important types of emphysema are centriacinar (or 
centrilobular) and panacinar (or panlobular). 
 The anatomic patterns of emphysema suggest specific pathogenetic 
mechanisms. The use of CT scans now allows the clinician to more 
carefully define the type of emphysema and to quantify it better. 
 
Proximal Acinar Emphysema : 
 Proximal acinar emphysema refers to those types of emphysema that 
begin in the respiratory bronchioles.
55
 Scarring and focal dilation of the 
bronchioles and of the adjacent alveoli result in the development of an 
26 
 
enlarged air space or microbulla in the center of the secondary lung 
lobule. Air space enlargement spreads peripherally from the centriacinar 
region. This type of emphysema includes focal emphysema and 
centriacinar emphysema. 
Focal Emphysema: 
 A form of centriacinar emphysema, occurring in persons who have 
had heavy exposure to a relatively inert dust such as coal dust, is called 
focal emphysema Large numbers of pigment-laden macrophages are 
noted in association with focal emphysema, which is distributed through 
the lungs. 
Centriacinar Emphysema: 
 Centriacinar emphysema is the form of emphysema most frequently 
associated with prolonged cigarette smoking in persons who have had no 
unusual dust exposure. This lesion involves the upper and posterior 
portions of the lungs more than the lower portions. 
Panacinar emphysema: 
 Diffuse panacinar emphysema is the lesion most often associated with 
alpha 1 anti-trypsin deficiency; the emphysema is usually more severe at 
the bases than at the apices. 
  Congenital lobar overinflation or emphysema results in infancy from 
bronchial atresia, most often in the apicoposterior segmental bronchus of 
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the left upper lobe; available information suggests that the accompanying 
emphysema is panacinar in type.
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 Panacinar emphysema have also been observed in intravenous 
methylphenidate users. 
Distal Acinar Emphysema: 
 In contrast to other forms of emphysema that tend to be generalized, 
distal Acinar Emphysema which is also known as paraseptal or subpleural 
emphysema, is localized along fibrous interlobular septa or beneath the 
pleura. 
  The remainder of the lung is often spared, so pulmonary function 
may be normal or nearly so despite the presence of many superficial areas 
of locally severe emphysema. This is the type of emphysema that 
produces the apical bullae giving rise to simple spontaneous 
pneumothorax in young persons. 
 
Air Space Enlargement with Pulmonary Fibrosis: 
 Another type of localized emphysema, air space enlargement with 
pulmonary fibrosis, is commonly seen as an inconsequential lesion 
adjacent to scars. At times, the air space enlargement may be quite 
extensive and may be important clinically, arising as a complication of 
fibrosing diseases such as tuberculosis, silicosis, and sarcoidosis.
55
 The 
underlying disease is usually evident radiographically, with extensive 
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linear or nodular shadows evident along with the enlarged air spaces. Air 
space enlargement with fibrosis is the anatomic lesion underlying 
emphysema associated with the pulmonary apical cap. Honeycombing or 
the end-stage of interstitial lung disease is different from air space 
enlargement with fibrosis. In honeycombing, cystic spaces 0.5 to 2 cm in 
diameter are located mainly in the periphery of the lung, although they 
can sometimes be widespread. The spaces have dense fibrous walls and 
are mostly lined by bronchiolar epithelium. To differentiate air space 
enlargement due to fibrosis from COPD, definitions of COPD are used to 
exclude fibrosis. 
  However, this is problematic because scarring, particularly in the 
small airway subepithelial space, is often a consequence of cigarette 
smoking and a contributing factor to airflow obstruction in COPD. In 
addition, collagen accumulates around larger disrupted air spaces. Hence, 
fibrosis and emphysema might be less distinct than we have previously 
believed. 
Cell Death: 
 Alveolar destruction resulting in air space enlargement requires loss 
of both cells within the alveolar space as well as the ECM components. 
Traditional theories suggest that the primary event is release of 
inflammatory cell proteinases resulting in degradation of lung ECM. 
Because cell viability requires cell-matrix attachment via integrins, loss 
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of matrix disrupts the contact and predisposes to cell death. Experimental 
models show that non inflammatory cell death can initiate air space 
enlargement.  
 Following cell death, presumably, proteinases may be released 
directly or inflammation initiated that subsequently degrades the ECM.  
Repair: 
 Destruction in emphysema is followed by aberrant repair of alveolar 
cells and matrix resulting in coalesced and enlarged air spaces with 
depleted and disordered parenchymal elastic fibers and excessive, 
abnormally arranged collagen. Elastin is the principal component of 
elastic fibers. Under normal conditions, elastin synthesis in the lung 
begins in the late neonatal period, peaks during early postnatal 
development, continues to a much lesser degree through adolescence 
paralleling lung growth, and stops in adult life. Multiple cell types are 
responsible for elastin synthesis in the lungs and associated structures. 
Elastin is resistant to most proteinases and lung elastin normally lasts a 
human life span, despite virtually absent elastin synthesis in the normal 
adult lung. 
 Following elastolytic injury, it is not known whether normal elastic 
fibers can be properly formed in the lung after the period of growth and 
development. 
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Bullae: 
 Bullae are areas of marked focal dilation of respiratory air spaces that 
may result from coalescence of adjacent areas of emphysema, from 
locally severe panacinar emphysema, or from a ball-valve effect in the 
bronchi supplying an emphysematous area.
56
 The bullae may be simple 
air spaces or may retain the trabeculae of the emphysema that led to them. 
Most frequently, bullae occur as a part of widespread emphysema. 
Although locally severe emphysema of any type can give rise to bullae, 
giant bullae are particularly likely to complicate distal acinar emphysema. 
In the setting of bullae, the amount of emphysema in adjacent lung 
without bullae varies. In distal acinar emphysema, the emphysematous 
changes may be confined to the bullous areas; however, if these bullae 
become large and compress adjacent lung tissue, they may have 
important physiologic consequences. 
Blebs and Cysts 
 Blebs are intrapleural collections of air and are, therefore, a form of 
interstitial emphysema. They may be a complication of interstitial 
emphysema in the newborn period or a complication of pulmonary 
barotrauma complicating mechanical ventilation. They may also be a part 
of the spontaneous pneumomediastinum of adults. Ruptured blebs are a 
cause of spontaneous pneumothorax. 
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 Cysts in the lung are air spaces lined by epithelium, which usually 
have the characteristics of bronchial epithelium. They are classically 
known as intrapulmonary bronchogenic cysts and usually occur near the 
tracheal bifurcation, but they may be seen more peripherally in the lung 
parenchyma. 
 Air spaces with fibrous walls, as seen in sarcoidosis and open healed 
of tuberculous cavities, are sometimes referred to as “cysts.” As described 
previously, they are better referred to as “air space enlargement with 
fibrosis.” 
Pulmonary Arteries: 
 Pulmonary hypertension is an important and dreaded complication of 
COPD. Various mechanisms by which COPD contributes to pulmonary 
hypertension are: 
1. Endothelial dysfunction : endothelial dysfunction refers to an imbalance 
between the vasoconstrictors and vasodilators elaborated by the 
endothelium, as a result of which there is vasoconstriction of pulmonary 
vessels. 
2. Vascular remodeling : The most consistent change in a pulmonary 
vasculature is intimal proliferation and thickening due to smooth muscle 
proliferation and deposition of collagen and elastin fibres. 
3. Emphysematous changes may also occur in the pulmonary capillary bed.              
4. Hypoxia: Hypoxia induced vasoconstriction. 
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Smoking induced endothelial dysfunction occurs early in the disease 
course and leads onto further vascular damage. 
 
CLINICAL FEATURES OF CHRONIC OBSTRUCTIVE 
PULMONARY DISEASE: 
History: 
 Cough and dyspnea are the most common symptoms reported by 
patients with COPD. 
 Dyspnea is typically present only with exertion until late in the course 
of the disease. . A productive cough should not be suppressed and a 
chronic daily cough is predictive of frequent exacerbations.
57 
 Sputum production is insidious in its onset and, in the majority of 
patients, it is scanty. Sputum production may also relate to smoking 
status, with current smokers having much more production. The sputum 
is usually mucoid but becomes purulent during exacerbations. Following 
smoking cessation, cough and sputum may become transiently more 
difficult, but symptoms generally improve following smoking cessation.
58 
 Hemoptysis complicating chronic bronchitis is usually occurs in 
association with an exacerbation.
59
 However, other etiologies of 
haemoptysis mainly lung cancer, should be kept in mind in this 
susceptible population.
60 
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 Dyspnoea, especially with exertion, is usually the presenting 
symptom and, as the disease progresses, occurs with less and less effort. 
Dyspnoea in COPD patients probably results from dynamic 
hyperinflation that worsens with increasing respiratory rate. As a result, 
many patients will avoid dyspnoea by avoiding exertion and may become 
exceedingly sedentary. 
 Exacerbations, which are characterized by increased cough, sputum, 
dyspnoea, and fatigue, are increasingly frequent as the disease worsens. 
They generally resolve over a few weeks, but full recovery may take 
months. Exacerbations may be difficult to distinguish from other acute 
causes of dyspnoea, cough, and/or sputum including pneumonia, 
congestive heart failure, pulmonary embolism, or pneumothorax without 
radiologic or laboratory evaluation. 
 
Physical examination: 
 Early inspiratory coarse crackles.   
 Rhonchi are more prevalent in patients complaining of dyspnoea and 
are usually present during both inspiration and expiration. 
 The most consistent finding in patients with symptomatic COPD is 
the prolonged expiratory time, which is best determined by listening over 
the larynx during a forced expiratory manoeuver. Prolongation of the 
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expiratory phase longer than the normal 4 seconds is indicative of 
significant obstruction.  
Severe COPD patients may present with 
 Barrel-shaped chest 
 Purse-lipped breathing 
 Emaciation 
 Inguinal hernias. 
 Tripoding 
  Position observed in severe COPD patients that is sitting forward and 
leaning on their elbows, or supporting their upper body with extended 
arms. This position stabilizes the shoulder girdle and helps to maximize 
intrathoracic volume. 
 Pulmonary hypertension may develop in patients with severe COPD 
and may present with 
 A loud and palpable pulmonary component of the second heart 
sound 
 Elevated jugular venous pressure 
 Bilateral pedal oedema 
 Congestive hepatomegaly 
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SYSTEMIC MANIFESTATIONS AND COMORBIDITIES OF 
COPD 
Cardiovascular system:  
 Infarction 
 Arrhythmia 
 Congestive heart failure 
 Hypertension 
The most common cause of death among COPD patients is coronary 
artery disease.
61
 Systemic inflammation plays a major role in the 
pathogenesis of atherosclerosis 
Hypercoagulability: 
Hypercoagulability due to systemic inflammation, account for increased 
risk of deep venous thrombosis and pulmonary embolism in COPD 
patients. 
 Stroke 
 Pulmonary embolism 
 Deep vein thrombosis 
Other systemic manifestations: 
 Weight loss 
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 Diabetes Mellitus and metabolic syndrome 
 Osteoporosis 
 Anaemia 
 Anxiety 
 Depression 
 Lung cancer 
 COPD patients may have a higher incidence of depression
63
 which 
may also result from systemically active inflammatory mediators. 
 Lung cancer is also a long term sequelae in COPD patients with 
smoking having an additive effect. 
INVESTIGATIONS: 
 The various investigation modalities available for the diagnosis of 
COPD are: 
1. Imaging modalities 
2. Pulmonary function tests 
3. Blood investigations 
Imaging: 
Imaging can be done with a chest x- ray or a computed tomography  
Chest X ray: 
Radiographic signs of emphysema may be due to the following reason: 
 hyperinflation 
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 vascular changes 
 bullae 
Overinflation of the lungs produces the following changes 
• Low flattened diaphragms. 
 Abnormally low diaphragms are present when the border of the 
diaphragm in the mid-clavicular line is at or below the anterior end of the 
sixth or seventh rib 
 Flattened diaphragms are present when the maximum perpendicular 
height from a line drawn between the costal and cardiophrenic angles to 
the border of the diaphragm is less than 1.5cm. 
• Increase in the retrosternal airspace: 
It can be demonstrated on the lateral film at a point 3 cm below the 
manubrium, occurs when the horizontal distance from the posterior 
surface of the aorta to the sternum exceeds 4.5 cm  
• An obtuse costophrenic angle on the posteroanterior or lateral chest 
radiograph. 
• The inferior margin of the retrosternal airspace is 3 cm or less from the 
anterior aspect of the diaphragm 
 
 Vascular changes associated with emphysema result from loss of 
alveolar walls and are shown on the plain chest radiograph by the 
following. 
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• A reduction in size and number of pulmonary vessels, particularly at the 
periphery of the lung. 
• Vessel distortion, producing increased branching angles, excess 
straightening or bowing of vessels. 
Chest X ray also used to rule to rule out the following diseases in COPD 
patients: 
Pneumonia 
Pneumothorax 
 On fluoroscopy the range of diaphragmatic movement, normally 6–
8cm and always greater than 3 cm, is often only 1cm in severe COPD. 
Occasionally the flattened diaphragms may be drawn upwards in parallel 
in inspiration, a motion different from true paradoxical movement due to 
paralysis of the phrenic nerve. In the latter, inspiratory sniffing gives rise 
to a sharp upward movement of the convex diaphragm, quite different 
from the slight upward movement of a flattened diaphragm in COPD. 
 Focal areas of translucency surrounded by hair-line walls represent 
bullae. These may be multiple, as part of a generalized emphysematous 
process, or localized 
Computed Tomography 
 In contrast to conventional radiography, computed tomography (CT) 
has the resolution needed to delineate and quantify subtle findings in the 
39 
 
chest and is therefore much more sensitive, particularly in the diagnosis 
of emphysema. There are several methods to assess COPD using CT. 
 CT density can be used to quantify emphysema, because loss of 
density is a characteristic feature. This permits estimates of both severity 
and extent of disease 
 The ability to distinguish bullae and to determine the location of 
disease is essential in determining whether individual patients are 
candidates for surgical therapy. 
Visual assessment of emphysema on CT reveals: 
 Areas of low attenuation without obvious margins or walls; 
 Attenuation and pruning of the vascular tree; 
 Abnormal vascular configurations. 
ECG Changes: 
An electrocardiography may reveal the following changes in COPD 
patients 
 P pulmonale 
 Right QRS axis deviation 
 Very low amplitude P, QRS, T wave complexes in lead I 
 SI,SII,SIII syndrome 
 Prominent terminal S Waves in leads I,II and III 
 Right bundle branch block 
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 All the above mentioned changes suggest a right ventricular 
enlargement hence they are not specific of COPD. Low amplitude 
complexes are due to increase in the anteroposterior diameter of the chest 
wall (barrel chest) in COPD patients. 
 
Echocardiography: 
Echocardiography can not only detect but also quantify the severity of 
COPD patients. The changes observed during an echocardiogram are:  
 Right ventricular hypertrophy and dilatation 
 Right atrial dilation 
 Right ventricular pressure overload pattern of interventricular 
septum 
 Right ventricular abnormal systolic function 
 Dilated pulmonary artery 
 Reduced left ventricular end systolic and diastolic volume 
 Tricuspid regurgitation  
 Elevated pulmonary artery systolic pressures. 
Pulmonary function tests: 
 Assessment of lung function is essential to establish a diagnosis and 
to access the severity of COPD. The most important test is spirometry. 
Measurement of lung volumes and diffusion capacity, which generally 
requires a specialized laboratory, may also be helpful, particularly in 
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determining whether airflow limitation is due to emphysema or airway 
disease. 
SPIROMETRY: 
 Simple spirometry is the most important test to diagnose and stage 
COPD. After taking a maximally deep breath, a subject exhales as 
forcefully as possible, and the volume of air exhaled is measured as a 
function of time. 
A reduction in FEV1/FVC ratio is diagnostic of airway obstruction. 
Because it may take some time for a patient to empty his or her lungs 
fully, particularly if COPD is present, the forced expiratory volume after 
6 seconds, FEV6, is recommended for use in most office settings. Not 
only is it easier to perform, but avoiding prolonged exhalation 
manoeuvers reduces the chance of syncope during the test. Because of 
variability in the FVC (or FEV6) measure, the FEV1/FVC ratio can 
establish a diagnosis of obstruction but is if airflow is abnormal, post 
bronchodilator testing should be performed. Correction to the normal 
range suggests a diagnosis of asthma and could exclude COPD. Partial 
correction, which may vary from day to day in an individual patient, may 
help to define therapeutic goals.  
 Though the FEV1/FVC ratio is the spirometric standard for 
diagnosing obstruction, the FEV1/FEV6 ratio is an acceptable surrogate. 
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 The FEV6 manoeuvre, which allows cessation of exhalation after 6 
seconds, has several advantages over the standard FVC manoeuvre. It is 
less physically demanding for the patient. It simplifies spirometric testing 
for the technician, shortens testing time, and has superior 
reproducibility.
65 
The FEV1/FEV6 ratio performs well in categorizing 
patients with obstruction with a sensitivity and specificity greater than 
90% compared with the FEV1/FVC ratio.
65-67
 Based on these findings, 
the National Lung Health Education Program has recommended 
replacement of FVC with FEV6.But FEV6 is not as sensitive as FVC at 
determining the presence of a restrictive respiratory impairment. 
Fig3. Spirometry pattern in lung disorders 
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SPIROMETRY MEASUREMENTS: 
Important clinical measurements are  
 Forced vital capacity (FVC): 
 The maximal volume of air forcefully exhaled after a maximal 
inspiration  
 Forced expiratory volume in 1 second (FEV1):  
 The amount of air exhaled during the first second of a FVC 
 Forced expiratory flow between 25% and 75% of the FVC 
(FEF25%–75%): 
 Reduction in FEF25%–75% is a spirographic manifestation of 
small airway dysfunction.
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 However, FEF25%–75% is a highly 
variable test that is dependent on exhalation time and is not specific 
for small airway disease in individual patients 
 Peak expiratory flow (PEF): 
 It is the maximum flow achieved during forced exhalation. PEF 
reflects the caliber of the large airways and is highly effort 
dependent. Although PEF is attractive because it can be measured 
using inexpensive handheld devices, it is a more variable measure 
than FEV1 and the correlation between PEF and FEV1 in patients 
with airway obstruction is poor. 
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Spirometry Acceptability Criteria: 
1. Good start of test 
 Sharp take-off without hesitation 
 Extrapolated volume < 5% or 0.15 L, whichever is greater 
2. Meet end-of-test criteria 
 Complete exhalation to residual volume 
 Plateau on volume-time curve 
 Exhalation time = 6 seconds (3 sec for children) 
3. Absence of artefacts 
 Cough, especially during first second of exhalation 
 Glottis closure 
 Hesitation or submaximal effort 
 Air leak 
 Obstructed mouthpiece 
 
Volume-Pressure Relationship 
Compliance of the lungs can be measured with an esophageal balloon. 
With severe emphysema, compliance of the lungs is increased. 
Measurement of the volume-pressure curve of the lung is a research 
procedure not generally used in routine clinical practice. 
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Diffusing Capacity 
 The single-breath diffusing capacity is decreased in proportion to the 
severity of emphysema because of the destruction of the alveoli and the 
loss of alveolar emphysema.
68
 It is also reduced in other diseases that 
destroy the alveolarcapillary bed. 
 
Sputum Examination 
 In stable bronchitis, sputum is mucoid, and microscopic examination 
reveals a predominance of macrophages. 
 Presence of eosinophils may indicate a greater likelihood to respond 
to inhaled glucocorticoid therapy  
 During the exacerbation, the number of organisms seen on Gram stain 
usually increases. The pathogens most often cultured from the sputum are  
• Streptococcus pneumoniae  
• Haemophilus influenzae.  
• Oropharyngeal commensal flora such as Moraxella catarrhalis  
However, cultures and gram stains are rarely necessary for initiation  of 
antimicrobial therapy unless the patient has sustained an exacerbation 
during or soon after receiving a course of antibiotic therapy. 
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Blood investigations: 
1. Complete haemogram: Both anaemia and polycythaemia can occur. 
Anaemia results from malnutrition and chronic inflammation. 
Polycythaemia is due to hypoxia induced stimulation of erythropoiesis  
2. An elevation of liver parameters especially alkaline phosphate can 
elevated if COPD results in a congested liver. 
3. Arterial blood gas analysis: In early stage: Mild or moderate hypoxemia 
without hypercapnia. In the later stages of the disease, hypoxemia tends 
to become more severe and may be accompanied by hypercapnia with 
increased serum bicarbonate levels. Hypercapnia is observed with 
increasing frequency as values of the FEV1 fall below 1 litre. Blood gas 
abnormalities worsen during acute exacerbations and may also worsen 
during exercise and sleep. Alterations in blood gases largely reflect 
alteration in ventilation-perfusion relationships. So spirometric values, 
which assess only airflow may be weakly correlated with blood gas 
abnormalities. 
4. Serum α1 antitrypsin level: 
In the following conditions measurement of α 1 antitrypsin level is 
warranted 
 Young onset 
 Non-smoker 
 Panacinar type 
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5. Systemic inflammatory markers: COPD is no longer considered a local 
inflammatory disease of the airways. It is a systemic disorder 
characterised by elevations in the acute phase reactants like CRP, 
Fibrinogen, inflammatory cytokines and chemokines. 
 
ASSESSMENT OF SEVERITY OF COPD: 
Severity of COPD is usually assessed by clinical methods and spirometry. 
Clinical methods include 
 Assessment of symptoms by mMRC scale and CAT score. Modified 
medical research council (mMRC) scale is a scale for assessing the 
degree of breathlessness. Patients are categorised into 5 groups (0-4) 
based on the limitation of activity due to dyspnoea.  
Grade 0 indicates dyspnoea only at strenuous exercise 
Grade 1 dyspnoea on walking up a slight hill or hurrying on a level 
ground 
Grade 2 walks slower than people of same group or dyspnoea while 
walking on one owns pace at level ground. 
Grade 3 patient stops for breath after few minutes of walk on level 
ground or walking 100 m 
Grade 4 patient is breathless even while dressing / undressing. 
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CAT score (COPD assessment test): 
 CAT score (COPD assessment test) is a questionnaire with 8 
questions each of which has a graded response from 0 to 5. Thus a 
maximum score of 40 is possible. The questionnaire includes  
 Cough  
 Sputum production  
 Chest tightness  
 Dyspnoea on exertion  
 Functional limitation of activity  
 Patient’s assessment of his disease  
 Sleep pattern and  
 Energy levels of the patient.  
 
Assessment of exacerbation risk: 
 Exacerbation is defined as worsening of the patient’s condition in a 
manner that is in excess of the normal day to day variation and requires a 
change in medication. An acute exacerbation includes increase in sputum 
production, increase in purulence or worsening dyspnoea. 
The best predictor of an exacerbation is the presence of a previously 
treated event. The most common cause of acute exacerbation is infections 
of which viral infections constitute the majority. 
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Assessment of severity by spirometry: 
 Spirometric diagnosis of COPD is made when a post bronchodilator 
FEV1/FVC ratio of < 0.7 is present. The spirometric assessment of 
severity is based on percentage of expected FEV1. 
 According to GOLD, 
Mild COPD is present when FEV is more than 80 % of predicted value.  
Moderate COPD have values between 50 and 80%. 
Severe COPD is characterised by FEV1 values between 30 and 50%. 
Very severe COPD indicates a FEV1 of less than 30% of predicted value 
or concomitant presence of respiratory failure and cor pulmonale. 
 
Assessment of severity with systemic inflammatory markers: 
 As we know COPD is not just a localised disease confined to the 
respiratory tract but a systemic disease. COPD patients present with 
higher levels of systemic inflammatory markers than the healthy control 
groups. In various studies, systemic inflammatory markers were not only 
elevated, but served as useful predictors of severity, risk of exacerbation 
and mortality in COPD patients. 
 In the ECLIPSE study which included about 2164 COPD patients, a 
marked rise in various inflammatory markers like IL 6, IL 8, CRP, 
fibrinogen, TNF α and MCP1 was observed. A point of interest in the 
50 
 
study was that, among all the inflammatory markers, IL 6 predicted 
severity and mortality better than others. 
 
CYTOKINES: 
 Cytokines are hormone like molecules that act mostly in a paracrine 
fashion to regulate to regulate immune response. They are generally 
secreted by lymphocytes, monocytes but can also be produced by 
endothelial cells, neuron and glial cells. 
Receptor for cytokines subdivided into 3 subfamilies: 
 Subfamily 1 includes the receptor for IL4 and IL7. They are 
usually homodimers. 
 Subfamily 2 includes the receptors for IL5 and IL6. They are 
usually heterodimers 
 Subfamily 3 includes receptors for IL2 and some other cytokines. 
They consist heterodimers with tac antigen. 
 Another subfamily of cytokines is the chemokine family. They are 
substances that attract neutrophils and other WBC to the area of 
inflammation. Over 40 chemokines are identified, whose role in cell 
growth and angiogenesis has also been established. 
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INTERLEUKIN 6: 
 Interleukin 6 is a cytokine, which has both pro-inflammatory and anti-
inflammatory actions. Its anti-inflammatory action produced by inhibiting 
TNF-α and IL6. 
 Previously it was recognised under various names like interferon β2, 
26-KD protein, B cell stimulating factor, cytotoxic T cell differentiation 
factor, hybridoma/plasmocytoma growth factor. 
 Interleukin 6 has received much attention only in the past two decade. 
Interleukin 6 was coined by Poupart et al in 1988.  
 
Cellular sources of IL6: 
• Type-2 helper T cells 
• Macrophages 
• Fibroblast 
• Adipocytes 
• Endothelial cells 
• Osteoblast 
• Smooth muscle cells of blood vessels. 
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Function of IL6: 
 IL6 has many molecular forms and each form has a different function. 
Acute phase reactant: 
 Acute phase reactant is a substance which is increased or decreased in 
response to an inflammatory stimulus. 
 IL6 is the most important stimulant for the acute phase reactant like 
CRP and serum fibrinogen from the liver. IL6 increases CRP levels by 
increasing the transcription process. 
Action on T cells: 
 IL 6 plays an important role in differentiation of T cells and their 
activation.It enhances the innate immunity by promoting the development 
of natural killer cells. It also promotes the differentiation of CD4 cells 
into T-helper cells by reinforcing the effect of IL2. 
Action on B cells: 
It is a potent stimulant for B cell differentiation and proliferation, 
Induces haematopoiesis 
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Fig 4: IL 6 and its functions 
Some of the diseases in which IL 6 contributes significantly to the 
pathogenesis are: 
 Rheumatoid arthritis, 
 Multiple myeloma and other malignancies 
 Diabetes mellitus 
 Atherosclerosis 
 Systemic lupus erythematosis  
 Coronary artery disease 
 Cirrhosis of liver 
 Castleman’s disease 
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ROLE OF IL 6 IN CHRONIC INFLAMMATION: 
 Under normal conditions, to an inflammatory stimulus there is a host 
response which acts as a natural defence mechanism to limit further 
damage. This acute response is mediated through neutrophils. 
 As the stimulus persists, the inflammatory response becomes chronic 
and this is no longer protective for the host. Once chronic inflammation 
sets in, further tissue destruction ensues resulting in more damage. 
 IL 6 plays a pivotal role in transforming the acute inflammation to a 
chronic process. It does so by enhancing the transformation of neutrophils 
into monocytes, which characterise chronic process. 
 
ROLE OF IL 6 in COPD: 
The concept of COPD being a systemic disease has already been 
emphasised and requires a mention here. Possible mechanisms by which 
COPD is considered a systemic inflammation are: 
• Smoking and air pollution 
• Spill over from the lung 
• Adipose tissue acting as a source of inflammation 
• Muscle acting as a source of inflammation 
• Genetic predisposition 
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The various inflammatory markers that are increased in COPD patients 
include: 
Cytokines: 
• Interleukin 6 
• Interleukin 10 
• Interleukin 12 
• Tumour necrosis factor α 
• Interleukin 1 β 
• Granulocyte colony stimulating factor 
Chemokines: 
• Interleukin 8(CXCL8) 
• Keratinocyte derived chemokine(CXCL 1) 
• Monocyte chemoattractant protein 1(MCP 1) 
• Macrophage inflammatory protein(MIP 2β and MIP 1) 
 IL 6 levels are found to be increased in sputum, exhaled breath and 
serum of COPD patients.  
 IL 6 as previously discussed mediates the chronic inflammatory 
process in COPD. IL 6 levels remain stable in circulation and this steady 
level contributes to the systemic manifestations of COPD. Systemic 
manifestations which IL 6 plays a major role include a widespread 
endothelial dysfunction, which leads to an increase in cardiovascular 
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mortality and morbidity. Insulin resistance, which contributes to 
metabolic derangements and diabetes mellitus, is also associated with 
increased circulating levels of IL 6. IL 6 by its action on osteoclasts, 
results in osteopenia and osteoporosis. Muscle wasting (sarcopenia) and 
depression are also associated features. 
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METHODOLOGY 
Study Centre: 
Institute of Internal Medicine, Madras Medical College and Rajiv Gandhi 
Government General Hospital, Chennai 
Duration of the Study: 
6 months 
Study Design: 
Case control study 
Sample Size: 
50 cases 
20 controls 
Inclusion Criteria:  
• Known case of COPD 
• Newly diagnosed cases of COPD 
 (COPD: FEV1/FVC < 0.70 post bronchodilator) 
  
58 
 
Exclusion Criteria: 
• Known malignancies 
• Known connective tissue disorders 
• Inflammatory disorders 
• Coronary artery disease 
• Acute stroke patients 
• Liver disease patients 
• Obesity 
• Diabetes mellitus 
 
Case and control selection: 
 50 patients with established diagnosis of COPD or newly 
diagnosed patients were enrolled in the study. COPD was defined by 
spirometric measurements. Any patient with clinical features suggestive 
of COPD was subjected to a spirometry and a FEV1/FVC value of less 
than 0.7 was the criteria. The spirometry was done post bronchodilator 
therapy. 20 controls with similar age and sex distribution were enrolled in 
the study. Informed consent was obtained. Institutional ethical committee 
clearance obtained. 
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Methods: 
Both cases and control population was evaluated with a 
questionnaire. A detailed history of symptomatology, smoking history 
and co morbid conditions were obtained. Pack years of the patients with a 
positive smoking history was calculated using the formula 
Pack years = (No. of cigarettes/day * No. of years of smoking) / 20. 
Patients with positive symptoms and history suggestive of COPD were 
further evaluated to assess the severity of the disease. The number of 
exacerbations per year was obtained. COPD assessment test score (CAT 
score) was assessed for all cases by a questionnaire which included the 
following aspects: 
1. History of cough 
2. Phlegm (mucus) in the chest 
3. Chest tightness 
4. Patient’s ability to walk up a hill or climb a flight of stairs 
5. Limitation of activity at home. 
6. Confidence in leaving home despite the existing condition 
7. Sleep pattern 
8. Sense of well-being. 
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Each aspect is answered by the patient. A graded score of 0 to 5 was 
given based on the patient’s response. Thus a maximum score of 40 was 
attainable. 
Patients were subjected to routine blood investigations. 
Spirometry: 
All cases enrolled in the study were subjected to spirometry. With 
patients comfortable and in sitting position, they were asked to exhale for 
atleast 6 seconds after maximal inspiration. The procedure was repeated 
if it was interrupted by cough, premature cessation of exhalation and 
obstruction of mouth piece. The following volumes were recorded. 
1. Forced vital capacity(FVC) 
2. FEV1(forced expiratory volume in the first second) 
3. FEV1/FVC ratio 
The measured FEV1 was compared against the predicted value and was 
expressed in percentage. Severity of COPD was graded according to the 
GOLD guidelines. 
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GOLD Staging Severity 
Spirometric values 
(FEV1/FVC<0.7) 
GOLD 1 Mild FEV1>=80% predicted 
GOLD 2 Moderate 50%<=FEV1<80% predicted 
GOLD 3 Severe 30%<=FEV1<50% predicted 
GOLD 4 Very severe FEV1<30% predicted 
 
Serum IL6 levels: 
 5 ml of venous blood was obtained from all cases and controls. 
Blood samples were centrifuged and serum separated. Serum IL 6 levels 
were estimated using ELISA technique. 
Data obtained by above methods were analysed by 
1. SPSS 15 
2. Chi square tests 
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OBSERVATIONS AND RESULTS 
Sex distribution: 
 
Out of 50 patients, 44(88%) were male patients and 6(12%) patients were 
female. Out of 20 controls, 17(85%) were male and 3(15%) were female. 
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SEX DISTRIBUTION 
MALE
FEMALE
Sex 
No. of subjects 
Cases Controls 
Male 44 17 
Female 6 3 
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Age Distribution: 
Age distribution No. of patients 
Cases Controls 
30-39 2 0 
40-49 11 6 
50-59 15 6 
60-69 17 6 
70 and above 5 2 
 
Among the 50 patients, majority of the patients (37 patients) were above 
the age of 50 years which accounted for 74% of total cases. 
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Smoking status: 
Among 50 patients, 40(80%) were smokers and 10(20%) were non 
smokers. All 6 females were non smokers.  
Smoking status No. of patients 
Smoker 40 
Non smoker 10 
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Smoking - pack years:  
Pack years No. of patients 
< 20 13 
20-39 24 
> 40 3 
 
More than 50% (27 out of 40) of smokers had pack years of 20 and 
above. 
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Symptomatology: 
Most common symptom observed in our study was dyspnoea (96%) 
followed by cough (80%). Clinical evidence of very severe COPD was 
present in 10% of cases.  
Symptomatology No. of patients 
Dyspnoea 48 
Cough 40 
Tightness of chest 28 
Wheeze 37 
Pedal edema 5 
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IL 6 levels comparison: 
In our study, mean IL 6 levels were elevated (9.434pg/ml) in COPD 
patients compared to the controls (0.68pg/ml) 
SUBJECTS IL-6 LEVELS (MEAN)(pg/ml) 
CASES 9.434 
CONTROLS 0.68 
 
By chi square test, p value<0.001**. 
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CAT score and IL 6 levels: 
CAT score of less than 10 was observed in 20 patients. Mean  IL 6 levels 
in the 20 patients was 5.05±1.72. It was much lower than the population 
of patients, (CAT score >=10, 30 patients) for whom the mean IL 6 levels 
were 12.35±3.49. 
CAT SCORE NO. OF PATIENTS 
IL 6 LEVELS  
(MEAN VALUE) 
(pg/ml) 
<10 20 5.05 
>=10 30 12.35 
 
By chi square test, p value<0.001**. 
0
2
4
6
8
10
12
14
CAT<10(n=20) CAT>=10 (n=30)
IL
6
 L
E
V
E
LS
(i
n
 p
g
/m
l)
 
IL6 LEVELS AND CAT SCORE 
69 
 
Exacerbation risk and IL 6 levels: 
For patients with less than 2 exacerbations per year the mean IL 6 levels 
were 5.343±1.75. 27 patients had 2 or more exacerbations per year and 
had a mean IL 6 value of 12.91±3.23.  
Exacerbation 
risk/year 
NO. OF PATIENTS 
IL 6 LEVELS  
(MEAN VALUE) 
(pg/ml) 
<2 23 5.343 
>=2 27 12.91 
 
By chi square test, p value<0.001**. 
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Spirometry grading and IL6 levels: 
Out of 50 patients, most number of patients were in the Grade II and 
GRADE III (34 patients); each grade had 17 patients. The mean IL 6 
levels were greatest for grade IV with a mean value of 16.69. The mean 
IL 6 values were observed to increase in an exponential manner with each 
grade. Statistical significance was observed for the below values.  
SPIROMETRY 
GRADING 
NO. OF PATIENTS 
IL 6 LEVELS  
(MEAN VALUE) 
(pg/ml) 
I 7 3.06 
II 17 6.29 
III 17 11.4 
IV 9 16.69 
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DISCUSSION 
 In our study of 50 cases, most of them were males with almost 
90% of the total number of cases. This clearly shows the higher 
prevalence of COPD in males. The possible explanation is that smoking 
is more prevalent in males, thus re-emphasising the importance of 
smoking as a risk factor for COPD. The 6 females had neither family 
history of COPD nor young by age. They developed COPD possibly due 
to passive smoking or environmental pollutants. But actual cause remains 
obscure and unidentified. 
 In our study, maximum number of patients was in the age group 
of 60-69 years. Again emphasis is on the chronic nature of the disease 
and long history of smoking. None of our patients were below the age of 
38.  
 Smoking history was present in 80% of cases, again stressing the 
role of smoking in COPD. Patients with a positive history of smoking 
were stratified on the basis of number of pack years. 48 % of patients had 
pack years between 20 and 40. A small proportion (6%) of patients had 
more than 40 pack years.as the pack years increased patients presented 
with more severe grades. The age of presentation was younger when 
compared to those with less number of pack years. 
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 Patients with COPD presented with dyspnoea as the major 
symptom. Dyspnoea was present in almost 96% of cases. Dyspnoea was 
graded by modified MRC scale.42 % of patients presented with grade II 
dyspnoea. Cough was the second common symptom followed by wheeze. 
Evidence of cor pulmonale in the form of pedal oedema was present in 
10% of cases thus classifying as very severe COPD as per the GOLD 
classification. 
 Serum IL 6 levels were compared between 50 cases and 20 
controls .IL 6 levels were significantly elevated in patients with COPD. 
IL 6 elevation in COPD patients confirms the chronic inflammatory 
nature of the disease which has been already discussed.  
 Giarcia rio et al
70
 (2010) demonstrated that inflammatory markers 
like IL 6, IL 8 and TNF α were elevated in COPD patients. An IL 6 value 
of 4.5 pg/ml was observed in COPD patients in the study compared to 
9.343pg/ml in our study. In the study, most of them were males (82%) 
and the mean age group was around 64 similar to data in our study 
group.. However, age and sex did not influence the level of IL 6 in COPD 
patients. 
 CAT score obtained by questionnaire. 20 patients had CAT score 
of <10 and 30 patients had CAT score of 10 or more. IL 6 levels were 
significantly elevated in the group with higher CAT scores. Since CAT 
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scores are based on clinical symptoms and well-being of the patient, IL 6 
levels can also be considered as marker of the underlying disease process 
and its clinical outcome. 
 Patients with fewer exacerbations(less than 2 per year) were 23 in 
number. IL 6 levels were lower in this group compared to the patient 
group which had 2 or more exacerbations per year. It is well known that 
number of exacerbations predict future exacerbations. With each 
exacerbation there is a decline in lung function and as the frequency of 
exacerbations  increase, the lung function decline is also rapid. Thus  IL6 
can be used as predictor to assess the exacerbation risk and also decline in 
lung function.  
 ECLIPSE
71
 study showed that IL 6 levels are associated with an 
increased risk of exacerbations. Abd Elmaksoud et al.(2010) 
demonstrated that higher IL 6 levels were associated with a rapid decline 
in lung function. Wedzikha et al
72
. showed that fibrinogen and serum IL 6 
levels are increased with acute exacerbations of COPD. 
 Spirometry grading as per GOLD criteria showed that 34 % 
presented with grade II and an additional 34% presented with Grade III. 
Very severe COPD (Grade IV) was present in 18% of cases, IL 6 levels 
increased with increasing grade of COPD. The values were also 
statistically significant. Spirometric grading is a predictor of mortality in 
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COPD. As IL 6 levels correlate strongly with the degree of spirometry 
grading, it can be considered as reliable marker to predict mortality in 
COPD patients. 
 Various studies demonstrate that serum levels of IL 6 predict 
mortality and outcome of patients with COPD.  
 Abd Elmaksoud et al.(2010)
74
 also correlated IL 6 levels with 
spirometric grading and showed highest IL 6 levels in grade III of COPD 
(grade IV patients were not included in the study). The mean  IL6 levels 
in the study was 11.26 pg/ml compared to 11.4 pg/ml.  
 BOLD
73
 study demonstrated an inverse relationship between 
FEV1 and IL 6 levels. 
 Thus IL 6 besides being an inflammatory marker has multiple 
roles in COPD patients. IL 6 as a marker in COPD patients parallels the 
clinical course, predicts exacerbation risk and predicts the decline in lung 
function. It also is a marker of disease severity and predicts morbidity and 
mortality in a given patient. 
  
75 
 
CONCLUSIONS 
In our study on 50 cases of COPD, the following conclusions were made: 
1. COPD is more common in males and is more common above the 
age of 50 years. 
2. Smoking is an important risk factor for COPD as evidenced by the 
number of smokers and prevalence of high pack years in COPD 
patients. 
3. Serum IL 6 levels are significantly elevated in COPD patients, not 
influenced by age or sex. 
4.  Serum IL 6 levels parallel the clinical course of the disease. 
5. Serum IL 6 levels predict the risk of exacerbation and decline in 
lung function. 
6. Serum IL 6 levels correlates with severity of the disease measured 
by spirometry. 
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PROFORMA 
SEVERITY OF CHRONIC OBSTRUCTIVE PULMONARY 
DISEASE AND ITS CORRELATION WITH SERUM 
INTERLEUKIN-6 LEVELS 
Name:      Age:   Sex: 
Address:       Occupation: 
Symptoms 
• Dyspnea 
• Cough 
• Sputum production 
• Chest discomfort 
• Wheezing 
• Abdominal distension 
• Swelling of legs 
• Weight loss 
• Fatiguability  
Past history: 
• Diabetes mellitus 
• Hypertension 
• Coronary artery disease 
• Bronchial asthma 
• Tuberculosis 
Personal history: 
• Smoking 
  
• Alcoholism 
General examination:: 
Pulse: 
Blood Pressure: 
Systemic Examination: 
CVS: RS: Abdomen:  CNS: 
 
COPD ASSESSMENT TEST SCORE: 
 
Investigations: 
Hemogram RFT 
TC  cells/mm
3
 Glucose (F)  mg/dl 
DC  Glucose (PP)  mg/dl 
ESR  mm/hr Urea  mg/dl 
Hb  g/dl Creatinine  mg/dl 
PCV  % Na+  mEq/l 
Platelets  lakhs/mm
3
 K+  mEq/l 
RBCs  million/mm
3
 
 
SERUM INTERLEUKIN-6 LEVELS: 
 
ECG: 
 
Echo Cardiogram: 
 
  
SPIROMETRY
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1 KUPPUSAMY 56 M 3 P A P P 22 24 2 3 12.6
2 AYYAVU 66 M 4 P P P P 32 28 3 4 16.5
3 RAMARAJU 48 M 2 P A P P 26 24 2 3 11
4 KARUPPANNAN 68 M 2 P A P P 20 19 2 3 12.4
5 ANGAMMAL 55 F 1 P A A A 0 4 1 1 3.6
6 JOSEPH 49 M 1 P A P A 12 11 1 2 6.6
7 MUTUSAMY 51 M 2 P A P A 14 7 2 2 4.8
8 RAJENDRAN 39 M 2 P A P A 12 9 1 2 5.5
9 SELVARAJ 57 M 2 P A P P 20 16 2 3 10.2
10 MOHAMAD IBRAHIM 62 M 2 A A P P 0 12 1 2 5.8
11 MARI 58 M 3 P A P P 30 26 3 4 17
12 PICHAYEE 51 F 1 P A P A 0 6 1 2 5.9
13 CHANDRAN 45 M 2 P A P A 24 9 1 2 7.5
14 RATHINAVEL 66 M 2 A A P P 20 14 1 2 7.8
15 KRISHNASAMY 59 M 2 P A P P 36 22 2 3 12.8
16 MALAIYAMMAL 47 F 0 P A A A 0 4 0 1 3.2
17 KUMARAN 52 M 3 P A P P 38 28 3 4 14.4
18 JEYAKUMAR 74 M 3 P A P P 30 21 2 3 11.6
19 KABALI 44 M 1 A A P A 0 5 0 1 2.5
20 RAJI 49 M 4 P P P P 36 32 3 4 16.6
21 VENKATACHALAM 68 M 3 P A P P 26 22 3 3 12
22 RAMAN 67 M 1 A A A A 0 8 1 2 5.9
23 SUNDARAM 46 M 1 P A A A 16 4 0 1 2.8
24 VELLAIYAN 76 M 4 A A P P 42 30 4 4 18.5
25 PANDI 53 M 3 P A P P 20 20 2 3 13
26 KUMARAVEL 68 M 3 P P P P 36 28 2 4 15.6
27 PARAMESWARAN 56 M 1 P A A A 14 2 0 1 2.8
28 SUBRAMANI 48 M 2 P A P P 24 16 1 2 6.5
29 RAJASEKAR 55 M 2 P A P P 30 18 2 3 10.6
30 KUPPAN 62 M 2 A A A A 28 8 1 2 6.6
31 RAVI 47 M 2 P A P P 36 22 2 3 11.1
32 VELU 63 M 1 A A A A 20 4 1 1 3.5
33 SUPPAN 61 M 3 P P P P 44 28 3 4 17.2
34 THIRUMOORTHI 58 M 3 P A P P 32 16 2 3 10.4
35 SEVANTHI 43 F 0 P A A A 0 4 1 2 6.6
36 SRIRANGAN 64 M 2 P A P P 34 12 2 3 12.2
37 RAMESH 38 M 2 P A P A 14 6 1 2 5.5
38 SULOCHANA 59 F 3 P A P P 0 22 2 3 8.6
39 VELLAIAN 65 M 2 A A A A 24 4 1 2 6.4
40 MANIKKAM 71 M 2 P A P A 20 8 1 2 6.8
41 THANGADURAI 48 M 1 P A A A 28 6 1 2 5.4
42 LOGANATHAN 66 M 2 A A A P 41 12 2 3 10.6
43 ARUNACALAM 56 M 1 P A A A 16 4 0 1 3
44 CINNAPONNU 62 F 2 P A P P 0 22 2 3 12.6
45 MALAISAMY 67 M 2 P P P P 35 22 2 4 16.6
46 DURAI 72 M 3 P A P P 27 22 2 3 12.6
47 NANTHAGOBAL 69 M 1 A A A A 29 4 1 2 8.2
48 RAJAN 55 M 2 P A P A 36 16 2 3 9.5
49 SUBRAMANI 61 M 1 P A P A 0 8 1 2 4.5
50 RAMAMOORTI 72 M 3 P A P P 31 26 3 4 17.8
Total 50
S.NO AGE SEX SERUM IL 6 LEVEL(pg/ml)
1 55 M 0.5
2 64 M 0.7
3 67 M 1.1
4 40 M 0.4
5 72 M 1.2
6 56 M 0.6
7 45 M 0.5
8 49 F 0.4
9 59 M 0.6
10 67 M 0.8
11 61 M 0.7
12 43 M 0.4
13 67 M 0.9
14 54 F 0.5
15 58 M 0.8
16 62 M 0.6
17 49 M 0.4
18 70 M 1.2
19 45 M 0.6
20 51 F 0.7



